NasdaqGM - Nasdaq Real Time Price USD

Amicus Therapeutics, Inc. (FOLD)

10.55 +0.21 (+2.03%)
As of 11:08 AM EDT. Market Open.
Loading Chart for FOLD
DELL
  • Previous Close 10.34
  • Open 10.40
  • Bid 9.05 x 100
  • Ask 11.88 x 100
  • Day's Range 10.26 - 10.57
  • 52 Week Range 9.70 - 14.57
  • Volume 259,744
  • Avg. Volume 3,024,344
  • Market Cap (intraday) 3.125B
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) --
  • EPS (TTM) -0.51
  • Earnings Date May 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.75

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

amicusrx.com

517

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FOLD

Performance Overview: FOLD

Trailing total returns as of 5/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

FOLD
25.65%
S&P 500
8.92%

1-Year Return

FOLD
13.17%
S&P 500
25.60%

3-Year Return

FOLD
9.90%
S&P 500
23.65%

5-Year Return

FOLD
25.81%
S&P 500
77.17%

Compare To: FOLD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FOLD

Valuation Measures

Annual
As of 5/6/2024
  • Market Cap

    3.06B

  • Enterprise Value

    3.22B

  • Trailing P/E

    --

  • Forward P/E

    72.99

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.64

  • Price/Book (mrq)

    19.12

  • Enterprise Value/Revenue

    8.07

  • Enterprise Value/EBITDA

    -34.98

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.96%

  • Return on Assets (ttm)

    -6.12%

  • Return on Equity (ttm)

    -107.04%

  • Revenue (ttm)

    399.36M

  • Net Income Avi to Common (ttm)

    -151.58M

  • Diluted EPS (ttm)

    -0.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    286.2M

  • Total Debt/Equity (mrq)

    277.86%

  • Levered Free Cash Flow (ttm)

    -25.89M

Research Analysis: FOLD

Analyst Price Targets

14.00
18.75 Average
10.55 Current
22.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: FOLD

Fair Value

10.55 Current
 

Dividend Score

0 Low
FOLD
Sector Avg.
100 High
 

Hiring Score

0 Low
FOLD
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
FOLD
Sector Avg.
100 High
 

People Also Watch